June 7, 2012 Volume 33, No. 32
Mizzou researchers bring hope to people with rare neurological condition
Insights from new model may aid development of therapeutic interventions
MU scientists have created a genetically modified mouse that mimics key features of Charcot-Marie-Tooth disease, an inherited neuromuscular disease infecting some 150,000 people in the United States.
Charcot-Marie-Tooth, or CMT, is a group of progressive disorders that harms the peripheral nervous system, the part that connects the brain and spinal cord to things like muscles.
The disease largely affects the distal nerves, which are those running to the feet and hands, and can progress to include the legs and arms.
“Wasting and weakening of the muscles occur because the distal nerves are either dying or not functioning properly,” said Michael Garcia, study leader and associate professor of biological sciences. “The condition can be very debilitating depending on the muscles affected and the degree to which they are affected.”
The breakthrough was reported in a recent edition of the online journal Genes, Brain, and Behavior.
No cure exists for CMT, but Garcia hopes that insights gleaned from the new mouse model may aid the development of therapeutic interventions.
“By learning about the basics of disease initiation and progression, perhaps we can soon test therapeutics designed to stop or reverse the pathology,” he said.
Garcia and colleagues created the mouse model by inserting a mutated copy of a human gene into a fertilized mouse egg cell. Similar mutations in that particular gene have been linked to a specific form of CMT, known as Type 2e, in humans.
The cells were then implanted into female mice. The offspring that contained the mutated human gene were reared and observed for signs of CMT.
At four months of age, the mice developed symptoms shared by humans with CMT Type 2e, including muscle wasting and weakness, foot deformities, and reduced mobility. No significant neural problems or detachment of the nerves from the muscle were observed in the mice, which surprised the scientists.
“With such severe muscle atrophy we expected to see a loss of nerve connections on the muscles, but they are all there, and they look relatively healthy,” said Garcia, who is also an investigator in the Christopher S. Bond Life Sciences Center.
The finding was surprising since another mouse model, which also mimicked CMT Type 2e, showed nerve detachment. This other mouse model, developed by a team in Canada, had a mutation in the same gene but at a different site in the genetic code. According to Garcia, the lack of nerve detachment observed in his mouse model may point to different underlying mechanisms for CMT Type 2e.
In a follow-up study, Garcia and colleagues showed that the mice they engineered also developed an abnormal gait. The scientists evaluated the gait using a so-called CatWalk system, a device that uses light and a high-speed camera to capture certain dynamics of a running mouse’s footfalls.
Abnormal gaiting was observed as a decreased paw print overlap and increased hind limb drag on the left side of the body, the authors report in the study.
A high-stepped gait is characteristic of people with CMT. Weakness of the foot and leg muscles often results in foot drop, an inability to move the ankle and toes properly, which is compensated for by raising the foot higher.
“It’s an exciting time for CMT Type 2e,” Garcia said. “With two really good mouse models, we’re now in a powerful position to begin to ask questions about how the disease initiates and how it progresses.”